Abstract
Rhinoviruses are the most common causes of viral respiratory infections and complications caused by viral respiratory infections in patients with underlying lung disease. Major recent therapeutic advances include the development of capsid-function inhibitors (pleconaril), inhibitors of 3C protease (AG7088), and recombinant soluble intercellular adhesion molecule (sICAM)-1, all of which exhibit potent antirhinoviral activity in vitro and varying activity in clinical trials. Pleconaril and AG7088 have shown the most promise and are the most advanced in clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
